Search

Displaying results 5631 - 5640 of 10000 in total
  1. Drug

    PYM50018

    go.drugbank.com/drugs/DB05126
    Experimental

    PYM50018 is a patented, orally active, neuroprotective and neuroregenerative compound. It is developed for the treatment of amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease). … When administered orally to a transgenic pre-clinical model of ALS, PYM50018 delays the loss of muscle strength and extends survival time.

  2. Drug

    Surotomycin

    go.drugbank.com/drugs/DB12076
    Investigational

    Surotomycin is non-inferior to vancomycin and offers a promising alternative for the treatment and prevention of C. diff infection. … It is a benzenebutanoic acid derivative patented by Cubist Pharmaceuticals, Inc. as antibacterial agents for the treatment of Gram-positive infections.

  3. Drug

    Pexmetinib

    go.drugbank.com/drugs/DB16294
    Investigational

    Pexmetinib is under investigation in clinical trial NCT04074967 (Study of ARRY-614 Plus Either Nivolumab or Ipilimumab).

  4. Drug

    Penimepicycline

    go.drugbank.com/drugs/DB13264
    Experimental

    Penimepicycline is a tetracycline-class antibiotic. It is mentioned on List A produced by the Government of Canada, which is a list of antimicrobial active pharmaceutical ingredients [L2791].

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  5. Drug

    Myrcludex B

    go.drugbank.com/drugs/DB14853
    Investigational

    Myrcludex B is under investigation in clinical trial NCT03546621 (A Multicenter, Open-label, Randomized Clinical Study to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination

  6. Drug

    ZYC300

    go.drugbank.com/drugs/DB04986
    Investigational

    ZYC300 is a plasmid DNA of CYP1B1 encapsulated in biodegradable poly-DL-lactide-coglycolide microparticles. … It is designed as a vaccine, intended to increase immune system sensitivity to CYP1B1, an enzyme highly prevalent in tumor cells.

  7. Drug

    Muraglitazar

    go.drugbank.com/drugs/DB06510
    Investigational

    Muraglitazar (Bristol-Myers Squibb/Merck) is a new agent under investigation for the treatment of patients with type 2 diabetes. … In addition to improvements in blood glucose and hemoglobin A1c (HbA1c), muraglitazar treatment is associated with a substantial reduction in triglycerides (TGs), an increase in HDL-C, and a modest decrease

  8. Drug

    Romifidine

    go.drugbank.com/drugs/DB11543
    ExperimentalVet approved

    This drug's chemical structure closely resembles that of clonidine, however, romifidine is not approved for use in humans. … Romifidine is a veterinary drug utilized as a sedative primarily in large animals, most frequently horses. It is also used less commonly in a wide variety of other animal species.

  9. Drug

    QazCovid-in

    go.drugbank.com/drugs/DB16441
    Investigational

    The QazCovid-in vaccine, an inactivated vaccine, was developed and tested in the Kazakh Research Institute for Biological Safety Problems[L30628].

  10. Drug

    Devafidugene civaparvovec

    go.drugbank.com/drugs/DB16790
    Investigational

    It uses proprietary zinc finger nucleases (ZFN) that insert a functional copy of the alpha-L-iduronidase (IDUA) enzyme. … Developed by Sangamo Therapeutics, Inc., devafidugene civaparvovec is being investigated for the treatment of mucopolysaccharidosis Type I (MPS I).[L46716]